Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) unit Jinzhou Avanc Pharmaceutical obtained approvals for two drug registration applications from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.

The regulator approved the application for the Famotidine Injection for the indication of gastrointestinal bleeding caused by peptic ulcers, as well as gastric and duodenal mucosal erosive bleeding.

The second application was approved for an additional indication of the Fovinaciclib Citrate Capsules to treat locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine therapy.